A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)

Severe Aplastic Anemia Clinical Trial

— TransIT  

Official title:

A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation With Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05600426
• Other study ID #: IRB-2020-0438
• Secondary ID: 1UG3HL157564-01A
• Status: Recruiting
• Phase: Phase 3
• Start date: January 25, 2023
• Est. completion date: December 2029

Study information

• Verified date: June 2024
• Source: Boston Children's Hospital
• Contact: Leah Cheng, MA
• Phone: 857-218-4731
• Email: leah.cheng[@]childrens.harvard.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Severe Aplastic Anemia (SAA) is a rare condition in which the body stops producing enough new blood cells. SAA can be cured with immune suppressive therapy or a bone marrow transplant. Regular treatment for patients with aplastic anemia who have a matched sibling (brother or sister), or family donor is a bone marrow transplant. Patients without a matched family donor normally are treated with immune suppressive therapy (IST). Match unrelated donor (URD) bone marrow transplant (BMT) is used as a secondary treatment in patients who did not get better with IST, had their disease come back, or a new worse disease replaced it (like leukemia).

This trial will compare time from randomization to failure of treatment or death from any cause of IST versus URD BMT when used as initial therapy to treat SAA.

The trial will also assess whether health-related quality of life and early markers of fertility differ between those randomized to URD BMT or IST, as well as assess the presence of marrow failure-related genes and presence of gene mutations associated with MDS or leukemia and the change in gene signatures after treatment in both study arms.

This study treatment does not include any investigational drugs. The medicines and procedures in this study are standard for treatment of SAA.

Description:

This study is a multi-center randomized phase III trial to compare the failure free survival between those randomized to IST vs 9-10/10 HLA matched URD BMT. The study will also address patient-reported outcomes and gonadal function in each arm and explore critical biological correlates including assessing germline genetic mutations associated with pediatric SAA that may lead to a predisposition to the disease and the risk of development of clonal hematopoiesis following IST vs BMT in pediatric and young adult SAA.

This clinical trial will randomize 234 children/AYA over 3.3-4.7 years at a 1:1 ratio between initial treatment with immune suppression therapy (IST) with horse ATG (hATG)/cyclosporine (CsA) versus well- matched (9-10/10 allele) unrelated donor (URD) bone marrow transplantation (BMT) using a regimen of rabbit ATG (rATG)/fludarabine/cyclophosphamide and 200 cGy TBI. Duration of subject participation for all study procedures in this study will be up to 2 years after treatment; a single later timepoint between 3 and 5 years will be collected to follow patients for specific protocol defined late effects and survival.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 234
• Est. completion date: December 2029
• Est. primary completion date: December 2029
• Accepts healthy volunteers: No
• Gender: All
• Age group: 0 Years to 25 Years

Eligibility

Inclusion Criteria:

To be eligible to participate in the randomized trial, an individual must meet all the following criteria:

1. Provision of signed and dated informed consent form for the randomized trial by patient and/or legal guardian.

2. Age =25 years old at time of randomized trial consent.

3. Confirmed diagnosis of idiopathic SAA, defined as:

1. Bone marrow cellularity <25%, or <30% hematopoietic cells.

2. Two of three of the following (in peripheral blood): neutrophils <0.5 x 10^9/L, platelets <20 x 10^9/L, absolute reticulocyte count <60 x 10^9/L or hemoglobin <8 g/dL.

4. No suitable fully matched related donor available (minimum 6/6 match for HLA-A and B at intermediate or high resolution and DRB1 at high resolution using DNA based typing).

5. At least 2 unrelated donors noted on NMDP search who are well matched (9/10 or 10/10 for HLA-A, B, C, DRB1, and DQB1 using high resolution).

6. In the treating physician's opinion, no obvious contraindications precluding them from BMT or IST.

Exclusion Criteria:

1. Presence of Inherited bone marrow failure syndromes (IBMFS). The diagnosis of Fanconi anemia must be excluded by diepoxybutane (DEB) or equivalent testing on peripheral blood or marrow. Telomere length testing should be sent on all patients to exclude Dyskeratosis Congenita (DC), but if results are delayed or unavailable and there are no clinical manifestations of DC, patients may enroll. If patients have clinical characteristics suspicious for Shwachman-Diamond syndrome, this disorder should be excluded by pancreatic isoamylase testing or gene mutation analysis (note: pancreatic isoamylase testing is not useful in children <3). Other testing per center may be performed to exclude IBMFS.

2. Clonal cytogenetic abnormalities or Fluorescence In-Situ Hybridization (FISH) pattern consistent with pre- myelodysplastic syndrome (pre-MDS) or MDS on marrow examination.

3. Known severe allergy to ATG.

4. Prior allogeneic or autologous stem cell transplant.

5. Prior solid organ transplant.

6. Infection with human immunodeficiency virus (HIV).

7. Active Hepatitis B or C. This only needs to be excluded in patients where there is clinical suspicion of hepatitis (e.g., elevated LFTs).

8. Female patients who are pregnant or breast-feeding.

9. Prior malignancies except resected basal cell carcinoma or treated cervical carcinoma in situ.

10. Disease modifying treatment prior to study enrollment, including but not limited to use of androgens, eltrombopag, romiplostim, or immune suppression. Note: Supportive care measures such as G-CSF, blood transfusion support and antibiotics are allowable

Related Conditions & MeSH terms

• Anemia
• Anemia, Aplastic
• Severe Aplastic Anemia

Intervention

Drug:
• cyclosporine
cyclosporine

Procedure:
• Matched Unrelated Donor Hematopoetic Stem Cell Transplant
Matched Unrelated Donor (MUD) Hematopoietic Stem Cell Transplantation (HSCT)

Drug:
• horse anti-thymocyte globulin (ATG)
horse anti-thymocyte globulin (ATG)
• rabbit anti-thymocyte globulin (ATG)
rabbit anti-thymocyte globulin (ATG)
• Methotrexate
methotrexate
• Fludarabine
fludarabine
• Cyclophosphamide
cyclophosphamide

Radiation:
• low-dose total body irradiation (TBI)
low-dose total body irradiation (TBI)

Procedure:
• Immunosuppressive Therapy (IST)
Immunosuppressive Therapy (IST)

Locations

Country	Name	City	State
United States	University of Michigan	Ann Arbor	Michigan
United States	Children's Hospital of Atlanta/Emory	Atlanta	Georgia
United States	Children's Hospital Colorado	Aurora	Colorado
United States	University of Alabama at Birmingham	Birmingham	Alabama
United States	Boston Children's Hospital	Boston	Massachusetts
United States	Roswell Park Comprehensive Cancer Center	Buffalo	New York
United States	University of North Carolina	Chapel Hill	North Carolina
United States	Levine Children's Hospital	Charlotte	North Carolina
United States	Ann & Robert H. Lurie Children's Hospital of Chicago	Chicago	Illinois
United States	University of Chicago	Chicago	Illinois
United States	Nationwide Children's Hospital	Columbus	Ohio
United States	Children's Medical Center Dallas	Dallas	Texas
United States	Duke University	Durham	North Carolina
United States	University of Florida	Gainesville	Florida
United States	Helen DeVos Children's Hospital	Grand Rapids	Michigan
United States	Hackensack University Medical Center	Hackensack	New Jersey
United States	Texas Children's Hospital	Houston	Texas
United States	Indiana University Hospital/Riley Hospital for Children	Indianapolis	Indiana
United States	University of Mississippi Medical Center	Jackson	Mississippi
United States	Arkansas	Little Rock	Arkansas
United States	Children's Hospital Los Angeles	Los Angeles	California
United States	UCLA	Los Angeles	California
United States	University of Wisconsin Hospital and Clinics	Madison	Wisconsin
United States	St. Jude Children's Research Hospital	Memphis	Tennessee
United States	Nicklaus Children's Hospital	Miami	Florida
United States	Vanderbilt University Medical Center	Nashville	Tennessee
United States	Yale University	New Haven	Connecticut
United States	Cohen Children's Medical Center of New York	New Hyde Park	New York
United States	Children's Hospital NOLA	New Orleans	Louisiana
United States	Columbia University Medical Center	New York	New York
United States	Children's Hospital of the King's Daughter	Norfolk	Virginia
United States	Children's Hospital & Research Center Oakland	Oakland	California
United States	Children's Hospital of Orange County	Orange	California
United States	Stanford	Palo Alto	California
United States	Children's Hospital of Philadelphia	Philadelphia	Pennsylvania
United States	Phoenix Children's Hospital	Phoenix	Arizona
United States	Oregon Health & Science University	Portland	Oregon
United States	Washington University in St. Louis	Saint Louis	Missouri
United States	Johns Hopkins All Children's Hospital	Saint Petersburg	Florida
United States	University of Utah/Primary Children's Hospital	Salt Lake City	Utah
United States	Rady Children's Hospital San Diego	San Diego	California
United States	University of California San Francisco	San Francisco	California
United States	Maine Health	Scarborough	Maine
United States	Fred Hutchinson Cancer Center	Seattle	Washington
United States	Children's National Hospital	Washington	District of Columbia
United States	Nemours Children's Hospital, Delaware	Wilmington	Delaware

Sponsors (7)

Lead Sponsor	Collaborator
Boston Children's Hospital	Blood and Marrow Transplant Clinical Trials Network, Center for International Blood and Marrow Transplant Research, National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), North American Pediatric Aplastic Anemia Consortium, Pediatric Transplantation and Cellular Therapy Consortium

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary endpoint of this trial is time from randomization to treatment failure or death from any cause.	The median time to failure or death will be compared on the two arms using the log-rank test. Failure of IST is defined as the date that a second definitive therapy was recommended (BMT, second course of ATG) and failure of BMT defined as the date that a second definitive therapy was recommended (second BMT, course of ATG).	Randomization to 2 years post-randomization
Secondary	Comparison of subjects with failure of IST or BMT before or at 2 years	The proportion of subjects with failure of IST or BMT before or at 2 years. Failure of IST is defined as initiation of a second definitive therapy (BMT, second course of ATG) and failure of BMT defined as initiation of a second definitive therapy (second BMT, course of ATG).	Randomization to 2 years post-randomization
Secondary	Comparison of subjects with inadequate counts at 2 years among those who have not died or failed treatment.	The proportion of subjects with inadequate counts at 2 years among those who have not failed therapy or died. Adequate counts are defined as: Absolute Neutrophil Count (ANC) >1 x 10^9/L, Hemoglobin >10g/dL, and Platelets >50 x10^9/L.	Randomization to 2 years post-randomization
Secondary	Comparison of subjects on immune suppression therapy at 2 years among those who have not died or failed treatment.	The proportion of subjects on immune suppression therapy at 2 years among those who have not failed therapy or died. Immune suppression is defined as systemic therapies necessary to treat SAA or GVHD (cyclosporine, tacrolimus, etc.). Isolated treatment with topical agents will not be considered as immune suppression therapy.	Randomization to 2 years post-randomization
Secondary	Estimate the time from randomization to initiation of IST or BMT.	The median time in days from randomization to initiation of IST or BMT will be estimated. Initiation of therapy is first day of ATG for IST subjects, or day 0 (infusion day) for bone marrow transplant subjects.	Randomization through Day 100
Secondary	Comparison of the frequency of failure to receive primary assigned therapy (IST or BMT) and reasons for the failure.	The proportion of subjects who fail to receive randomized therapy and the frequency of reasons for failure.	Randomization through Day 100
Secondary	Comparison of the incidence of bacteremia, viremia, and invasive fungal infection in the first two years after randomization in the IST and BMT arms.	Proportion of subjects from the time of randomization in the first 2 years with each of the following: Documented bacteremia; Documented viremia; Documented invasive fungal infection (defined as confirmed or suspected fungal infection based upon imaging)	Randomization through two years post randomization
Secondary	Estimate the median time to T- and B-cell immune reconstitution the first year for the URD BMT Arm	Absolute CD3, CD4, CD8, CD19, and CD56 (NK cell) numbers will be tracked at 100 days, 180 days, 1 year and 2 years post initiation of therapy in URT BMT arm. IgG levels free of IVIG replacement will be collected at the same timepoints. The median time to T- and B-cell reconstitution will be estimated.	Initiation of therapy (Day 0) to 100 days, 180 days, 1 year and 2 years
Secondary	Comparison of overall survival at 1 and 2 years from randomization in both arms.	Proportion of subjects who have died at 1 year and 2 years after randomization for any reason.	Randomization to one year, randomization to two years
Secondary	Comparison of treatment-related mortality (TRM) at 1 and 2 years from randomization in both arms.	Proportion of subjects who have died at 1 year and 2 years after randomization due to treatment-related reasons. TRM is defined as death in recipients without relapse or progression of their disease. Non-medical, accidental causes of death, e.g., natural disasters, are not considered TRM.	Randomization to 1 year, randomization to 2 years
Secondary	Comparison of the median time from randomization to and rates of neutrophil recovery on both arms	The time from randomization to neutrophil recovery. Neutrophil recovery is defined as ANC 0.5 x109/L for 3 consecutive measures for neutrophils (recovery date is the first date).	Randomization to 100 days, 180 days, 1 year and 2 years
Secondary	Comparison of the median time from randomization to and rate of platelet recovery on both arms	The time from randomization to platelet recovery. Platelet recovery is defined as platelet levels >= 20 x10^9/L for 3 consecutive measures (recovery is the first date) with no platelet transfusions for 1 full week.	Randomization to 100 days, 180 days, 1 year and 2 years
Secondary	Comparison of the median time from randomization to and rates of red blood cell recovery on both arms	The time from randomization to red blood cell recovery. Red blood cell recovery is defined as RBC hemoglobin level >= 8g/dL and 10g/dL with no RBC transfusions for 4 weeks.	Randomization to 100 days, 180 days, 1 year and 2 years
Secondary	Comparison of the median time from initiation of therapy to and rates of neutrophil recovery on both arms	The time from initiation of therapy (defined as Day 1 for patients randomized to IST and Day 0 for patients randomized to URD BMT) to neutrophil recovery. Neutrophil recovery is defined as ANC 0.5 x109/L for 3 consecutive measures for neutrophils (recovery date is the first date).	Initiation of therapy to 100 days, 180 days, 1 year and 2 years
Secondary	Comparison of the median time from initiation of therapy to and rate of platelet recovery on both arms	The time from initiation of therapy (defined as Day 1 for patients randomized to IST and Day 0 for patients randomized to URD BMT) to platelet recovery. Platelet recovery is defined as platelet levels >= 20 x10^9/L for 3 consecutive measures (recovery is the first date) with no platelet transfusions for 1 full week.	Initiation of therapy to 100 days, 180 days, 1 year and 2 years
Secondary	Comparison of the median time from initiation of therapy to and rates of red blood cell recovery on both arms.	The time from initiation of therapy (defined as Day 1 for patients randomized to IST and Day 0 for patients randomized to URD BMT) to red blood cell recovery. Red blood cell recovery is defined as RBC hemoglobin level >= 8g/dL and 10g/dL with no RBC transfusions for 4 weeks.	Randomization to 100 days, 180 days, 1 year and 2 years
Secondary	Estimate the rates of engraftment in patients who are randomized to URD BMT.	Proportion of subjects with engraftment in patients who receive URD BMT.	Randomization to 3-5 years
Secondary	Estimate the rates of primary graft failure in patients who are randomized to URD BMT .	Proportion of subjects with primary graft failure in patients who receive URD BMT. Primary graft failure is defined as failure to achieve neutrophil recovery by Day +28 following a conditioning regimen induced neutrophil nadir < 0.5 x10^9/L.	Randomization to 3-5 years
Secondary	Estimate the rates of secondary graft failure in patients who are randomized to URD BMT .	Proportion of subjects with secondary graft failure in patients who receive URD BMT. Secondary graft failure will be defined as a fall in the neutrophil count after documented primary engraftment to < 0.5 x10^9/L sustained for more than three days that cannot be attributed to other causes such as drugs, infection, GVHD, etc., and is not responsive to G-CSF or GM-CSF.	Randomization to 3-5 years
Secondary	Estimate the rates of grade II-IV acute GVHD in patients who are randomized to URD BMT .	Proportion of subjects with grade II-IV in patients who receive URD BMT.	Randomization to 3-5 years
Secondary	Estimate the rates of grade III-IV acute GVHD in patients who are randomized to URD BMT.	Proportion of subjects with grade III-IV acute GVHD in patients who receive URD BMT.	Randomization to 3-5 years
Secondary	Estimate the rates of severe chronic GVHD in patients who are randomized to URD BMT.	Proportion of subjects with severe chronic GVHD in patients who receive URD BMT.	Randomization to 3-5 years
Secondary	Estimate the rates of response of patients randomized to IST	Proportion of subjects with IST response. IST response criteria is: Complete Response: Hemoglobin =10 g/dL and ANC =1x10^9/L and Platelets =100x10^9/L Very Good Partial Response: Hemoglobin =8 g/dL and ANC =0.5x10^9/L and Platelets =50x10^9/L Partial Response: Hemoglobin =8 g/dL and ANC =0.5x10^9/L and Platelets =20x10^9/L and transfusion independent No Response (failure): Hemoglobin <8 g/dL or ANC <0.5x10^9/L or Platelets <20x10^9/L Lost Response: A lost response is captured by not meeting hematologic response criteria at a particular time point after having an initial response (complete, very good partial, or partial), or the need for additional treatment.	Randomization to 100 days, 180 days, 1 year and 2 years
Secondary	Estimate the rates of failure of patients randomized to IST	Proportion of subjects with IST failure at 6 months (defined as Hemoglobin <8 g/dL or ANC <0.5x10^9/L or Platelets <20x10^9/L).	Randomization to 100 days, 180 days, 1 year and 2 years
Secondary	Describe the secondary therapies given and outcomes achieved for patients failing initial therapy	Collect secondary therapies given for failure of primary randomized therapy (BMT after IST, second course of IST, second BMT). For the outcome after subsequent therapy, the median survival time will be estimated.	Randomization to 3-5 years
Secondary	Comparison of rates of secondary MDS, AML, other subsequent neoplasms, and development of Paroxysmal Nocturnal Hemoglobinuria in both treatment arms for the duration of the trial.	Proportion of subjects in each treatment arm with i) subsequent neoplasms, ii) presence of a PNH clone at time of randomization who go on to develop symptomatic PNH through the duration of the protocol.	Randomization to 3-5 years
Secondary	Comparison of HR-QoL score between patients randomized to both arms	Change in score between baseline and two years and the trajectory of change over all timepoints.	Randomization to 2 years post-randomization, randomization to up to 5 years post-randomization
Secondary	Comparison of gonadal function values between patients randomized to both arms	Proportion of subjects with gonadal function values outside the expected percentile for that age.	Randomization to 1 year post-randomization, randomization to 2 years post-randomization, and randomization to up to 5 years post-randomization